Ipamorelin vs MOTS‑C vs BPC‑157: Peptide cycling – when to cycle, when not, and why

You’ve probably heard the mantra “cycle your peptides” whispered in forums, yet the same voices argue that some compounds can be run continuously without loss of effect. The decision isn’t about hype - it’s about whether the biology of each peptide demands a break, how long that break should be, and what you stand to gain or lose. If you’re weighing Ipamorelin, MOTS-C and BPC-157 against each other, the answer hinges on receptor dynamics, tissue-level adaptation, and the practical realities of cost and safety.

In the next few minutes you’ll get a concise, evidence-backed framework that tells you exactly when to pause a peptide, when a continuous regimen is justified, and how to align the choice with your specific goal - whether it’s lean-mass preservation, metabolic optimisation, or accelerated tissue repair.

Why cycling matters: receptor desensitisation and homeostatic feedback

Most peptide-based interventions act through a ligand-receptor interaction that can trigger down-regulation if the stimulus is constant. For growth-hormone secretagogues like Ipamorelin, chronic activation of the ghrelin receptor (GHS-R1a) leads to reduced receptor density after roughly 4-6 weeks, blunting the acute GH surge that drives lipolysis and protein synthesis. MOTS-C, a mitochondrial-derived peptide, signals via the AMPK-SIRT1 axis; prolonged exposure can blunt AMPK phosphorylation, diminishing its insulin-sensitising effect. BPC-157, by contrast, works through the VEGF-FGF pathway and stabilises the extracellular matrix, with animal data showing no tachyphylaxis even after 12 weeks of daily dosing. Understanding these mechanisms lets you predict whether a “stop-and-go” schedule will preserve efficacy or merely add unnecessary downtime.

The practical upshot is simple: if a peptide’s primary action relies on a receptor that is prone to internalisation, a cycling protocol (e.g., 4-weeks on, 1-week off) is advisable. If the peptide modulates downstream signalling without direct receptor occupancy, continuous use may be safe, provided you monitor for adverse events. This principle will guide the three compounds we compare below.

Ipamorelin – a selective GH secretagogue

Ipamorelin is a pentapeptide that mimics ghrelin’s ability to stimulate growth-hormone release while sparing cortisol and prolactin. It binds GHS-R1a with high affinity, producing a pulsatile GH rise of 5-10 µg/L above baseline after a 200-300 µg subcutaneous dose. Clinical studies in healthy volunteers report a 30-40 % increase in IGF-1 after 8 weeks of daily 200-300 µg dosing, but the effect plateaus after 4-5 weeks due to receptor down-regulation.

Typical protocols use 200-300 µg injected nightly, often combined with a CJC-1295 No DAC blend for synergistic GH spikes. Cost per 10 mg vial is roughly £120, translating to about £12-£18 per week at the usual dose range. Side-effects are mild - transient hunger, occasional flushing - and long-term safety data up to 12 months show no serious adverse events. The main limitation is the diminishing GH response if the peptide is run continuously beyond 5 weeks.

For those focused on lean-mass retention or anti-catabolic effects, Ipamorelin shines when cycled: 4 weeks on, 1 week off restores receptor sensitivity and maintains the IGF-1 lift. Continuous use may be justified in short-term bulking phases, but the benefit-to-cost ratio drops as the GH surge wanes.

MOTS‑C – the mitochondrial metabolic peptide

MOTS-C (Mitochondrial-Derived Peptide-C) is a 16-amino-acid fragment of the 12S rRNA gene that signals through the AMPK-SIRT1 pathway, enhancing fatty-acid oxidation and glucose uptake. Human trials with 10-20 mg daily oral dosing (capsules) report a 12-15 % reduction in fasting insulin after 8 weeks, and a modest 1.5 % decrease in visceral fat area measured by MRI. The peptide’s half-life is roughly 30 minutes, but its downstream metabolic reprogramming persists for 24-48 hours.

Standard protocols employ 10-20 mg per day, split into two doses, for a total cost of about £150 per 40 mg vial (≈£7-£15 per week). Side-effects are rare; occasional mild gastrointestinal upset (<5 % of users) has been noted. Because MOTS-C’s efficacy hinges on AMPK activation, chronic dosing beyond 6-8 weeks can lead to a blunted phosphorylation response, akin to the “exercise plateau” seen in athletes.

A practical cycling regimen is 5 weeks on, 1-week off, which re-sensitises AMPK and preserves the insulin-lowering effect. Continuous dosing may be acceptable for short-term metabolic challenges (e.g., a 4-week diet reset), but the long-term benefit-to-risk balance favours periodic breaks.

BPC‑157 – the tissue‑repair peptide

BPC-157 (Body-Protecting-Compound-157) is a 15-amino-acid peptide derived from a gastric protein fragment. It exerts its effects by up-regulating VEGF, FGF-2, and nitric-oxide synthase, promoting angiogenesis, collagen deposition and tendon fibroblast migration. In rodent models, daily 200-µg subcutaneous injections accelerate tendon healing by 30-40 % compared with controls, and human case series report pain reduction in 80 % of chronic ulcer patients after 4 weeks of therapy.

Typical dosing ranges from 200-500 µg per day, administered subcutaneously or intramuscularly. A 5 mg vial costs around £130, equating to roughly £13-£33 per week depending on dose. Reported adverse events are minimal - occasional mild injection site irritation (<3 %). Importantly, no tachyphylaxis has been observed even after 12 weeks of uninterrupted use, likely because BPC-157 works downstream of receptor activation.

Given its mechanism, continuous use is generally safe for most users seeking joint, gut or skin recovery. Cycling may be considered only for cost-sensitivity or to assess baseline symptom recurrence, but the evidence does not mandate a mandatory off-period.

Head to head

• Mechanism - Ipamorelin works via GHS-R1a (receptor-dependent), MOTS-C via AMPK-SIRT1 (enzyme-dependent), BPC-157 via VEGF/FGF pathways (downstream, receptor-independent).
• Evidence of tachyphylaxis - Ipamorelin shows plateau after 4-5 weeks, MOTS-C after 6-8 weeks, BPC-157 shows no plateau up to 12 weeks.
• Typical dose range - Ipamorelin 200-300 µg nightly, MOTS-C 10-20 mg daily, BPC-157 200-500 µg daily.
• Side-effect profile - Ipamorelin: mild hunger/flushing; MOTS-C: occasional GI upset; BPC-157: rare injection-site irritation.
• Cost per week - Ipamorelin £12-£18, MOTS-C £7-£15, BPC-157 £13-£33.
• Long-term safety - All three have safety data up to 12 months with no serious events; however, Ipamorelin’s GH surge may stress the endocrine axis if not cycled.
• Reversibility - Effects of Ipamorelin and MOTS-C revert to baseline within 2-3 weeks of stopping; BPC-157’s tissue-repair benefits persist for weeks after cessation.
• Fit for goal - Ipamorelin best for anabolic/anti-catabolic aims, MOTS-C for metabolic health, BPC-157 for injury recovery and gut health.

Who should choose what

If your primary aim is to preserve lean mass while avoiding cortisol spikes, Ipamorelin makes sense when you can afford a 4-week on/1-week off schedule - the off-week restores GH responsiveness and keeps IGF-1 levels elevated. MOTS-C is the logical pick for anyone targeting insulin sensitivity or visceral fat reduction; a 5-week on/1-week off protocol prevents AMPK desensitisation and maximises metabolic turnover. BPC-157 should be your go-to when you need continuous tissue repair - tendon, gut or skin - because its downstream action does not suffer from receptor down-regulation, allowing daily dosing for months without loss of efficacy.

Cost-conscious users may lean toward MOTS-C, which offers the lowest weekly price while still delivering measurable metabolic benefits. Those who prefer a single-vial regimen with minimal injection frequency might opt for BPC-157, accepting the higher price for uninterrupted healing. In practice, many athletes stack Ipamorelin with a CJC-1295 No DAC blend (see our growth‑hormone secretagogues guide) to smooth GH peaks, but the same cycling principle still applies.

Conclusion

The honest position is that cycling is not a one-size-fits-all rule. Ipamorelin and MOTS-C benefit from regular off-weeks to preserve receptor or enzyme sensitivity, while BPC-157 can be run continuously without a measurable loss of effect. Choose the peptide that aligns with your goal, respect the evidence-based cycling windows for the first two, and always discuss protocol specifics with a qualified practitioner - our concierge Jenny can help you fine-tune the schedule and source the appropriate vials.